ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 304

Juvenile Rheumatoid Arthritis and Future Risk for Cardiovascular Disease; A Multicenter Population-Based Study

Jason Anderson1, Katelyn Anderson1, Hanne Aulie2, Cynthia S. Crowson3, Thomas Mason II4, Stacy P. Ardoin5, Ann M. Reed6 and Berit Flato7, 1Mayo Clinic, Rochester, MN, 2Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 3Health Sciences Research, Mayo Clinic, Rochester, MN, 4Division of Rheumatology - Department of Medicine, Mayo Clinic, Rochester, MN, 5Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, 6Rheumatology, Mayo Clinic, Rochester, MN, 7Department of Rheumatology, Oslo University Hospital, Oslo, Norway

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease and juvenile arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Several studies suggest an increased frequency of cardiovascular disease (CVD) in patients with rheumatoid arthritis, but little is known about CVD risk in patients with juvenile rheumatoid arthritis (JRA). The objective of this study was to evaluate the frequency of CVD and CVD risk factors in adults with a prior diagnosis of JRA compared to controls.

Methods: A retrospective, partly population-based cohort study was independently conducted utilizing patients at two major academic institutions (Cohorts 1 and 2).  Each institution employed a unique methodology to evaluate for the common endpoint of clinical CVD outcomes and risk factor development with comparison to control groups of similar age and sex. Cohort 1 was an inception cohort of residents of a geographically defined area who were diagnosed with JRA in 1960-1993. CVD and CVD risk factors were ascertained via medical record review and telephone survey for the subset of patients currently aged ≥30 years. Cohort 2 included patients diagnosed with JRA in 1980-1985 who participated in a clinical exam or completed a survey in 2011-2012 (i.e. 29 year follow-up).

Results: Among 41 patients with JRA and 28 controls in cohort 1, 3 patients (7%) had CVD, compared to 0 controls (p = 0.43).  Of these, 1 patient had CVD prior to age 30 with ages at time of CVD diagnosis ranging from 21-39 years. Types of CVD included 1 patient with venous and arterial thrombosis, 1 patient with coronary artery disease and myocardial infarction, and 1 patient with angina pectoris. Analysis for the presence of CVD risk factors in Cohort 1 demonstrated 15 patients (56%) with hyperlipidemia, compared to 0 controls (p = 0.019). Twenty patients (49%) were ever smokers, compared to 10 controls (36%) (p = 0.004). Other risk factors including hypertension, diabetes mellitus, and family history of CVD were elevated in the JRA cohort but did not obtain statistical significance. Among 170 JRA patients with 29 year follow-up and 91 controls in Cohort 2, 2 patients (2%) had CVD, compared to 0 controls (p = 0.29). Types of CVD included 1 patient with myocardial infarction and 1 patient with angina pectoris and myocardial infarction. Analysis for the presence of CVD risk factors in Cohort 2 demonstrated 14 patients (8%) with hypertension, compared to 2 controls (2%) (p = 0.049). Ninety patients (54%) were ever smokers, compared to 36 controls (40%) (p = 0.028). Other CVD risk factors measured and elevated in the JRA cohort included use of antilipemic medication, use of antihypertensive medication, and CVD in first degree relative, but statistical significance was not obtained. The presence of diabetes mellitus was equal in the JRA cohort and control group for Cohort 2.

Conclusion: Certain CVD risk factors including hyperlipidemia, hypertension, and smoking appear to be more common among patients with JRA than in age-matched controls. There may be a trend toward increased numbers of CVD events, and occurrence of CVD at younger ages in patients with JRA, although statistical significance was not demonstrated in this study. Continued longitudinal follow-up of these cohorts and larger population-based studies are needed to establish a definitive relationship between JRA and CVD.


Disclosure:

J. Anderson,
None;

K. Anderson,
None;

H. Aulie,
None;

C. S. Crowson,
None;

T. Mason II,
None;

S. P. Ardoin,
None;

A. M. Reed,
None;

B. Flato,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/juvenile-rheumatoid-arthritis-and-future-risk-for-cardiovascular-disease-a-multicenter-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology